Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag in Chinese Adults With Persistent or Chronic Immune Thrombocytopenia
NCT06287567Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lusutrombopag in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2024; status: completed.
02
Drugs
lusutrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06287567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287567.